Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Exact Sciences Corporation    EXAS

EXACT SCIENCES CORPORATION

(EXAS)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/11/2021 01/12/2021 01/13/2021 01/14/2021 01/15/2021 Date
144(c) 148.42(c) 145.37(c) 147.29(c) 145.97(c) Last
5 769 116 2 241 526 1 672 475 1 339 698 1 528 542 Volume
+9.84% +3.07% -2.05% +1.32% -0.90% Change
More quotes
Financials (USD)
Sales 2020 1 465 M - -
Net income 2020 -396 M - -
Net cash position 2020 182 M - -
P/E ratio 2020 -53,1x
Yield 2020 -
Sales 2021 1 844 M - -
Net income 2021 -191 M - -
Net Debt 2021 126 M - -
P/E ratio 2021 -129x
Yield 2021 -
Capitalization 23 214 M 23 214 M -
EV / Sales 2020 15,7x
EV / Sales 2021 12,7x
Nbr of Employees 4 110
Free-Float 99,1%
More Financials
Company
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect... 
More about the company
Notations Surperformance© of Exact Sciences Corporation
Trading Rating : Investor Rating :
More Ratings
All news about EXACT SCIENCES CORPORATION
01/15EXACT SCIENCES CORP : Change in Directors or Principal Officers (form 8-K)
AQ
01/13EXACT SCIENCES : Licenses Targeted Digital Sequencing Method in Cancer Screening
MT
01/12EXACT SCIENCES : Oppenheimer Adjusts Price Target for Exact Sciences to $161 Fro..
MT
01/11INSIDER TRENDS : 90-Day Insider Buying Trend Reduced with Sale of Guidewire Soft..
MT
01/11SECTOR UPDATE : Narrow Rise for Most Health Care Stocks
MT
01/11EXACT SCIENCES : Projects Q4 Revenue Above Street Forecasts
MT
01/08EXACT SCIENCES : EXAS) Insider Makes Significant Share Sale
MT
01/07INSIDER TRENDS : Exact Sciences Insider Extends 90-Day Selling Trend
MT
01/05Jefferies, Exxon rise; Exact Sciences, WW International fall
AQ
01/05EXACT SCIENCES : Sees Q4 Revenue To Exceed Market Expectations
MT
01/05EXACT SCIENCES CORP : Results of Operations and Financial Condition, Change in D..
AQ
2020EXACT SCIENCES : RxPONDER Study Results Demonstrate that the Oncotype DX® Test C..
PU
2020EXACT SCIENCES : Oppenheimer Adjusts Exact Sciences' Price Target to $153 From $..
MT
2020EXACT SCIENCES : $10 million grant from exact sciences to support stand up to ca..
PU
2020EXACT SCIENCES : Significant Insider Selling in Shares of Exact Sciences (EXAS) ..
MT
More news
News in other languages on EXACT SCIENCES CORPORATION
2020EXACT SCIENCES CORPORATION : Veröffentlichung des Jahresergebnisses
2020EXACT SCIENCES CORPORATION : publication des résultats annuels
2019STOCK MARKET PARIS : Attention, semaine très chargée !
2019EN DIRECT DES MARCHES : Sanofi, Airbus, Air France KLM, CNP, Refinitiv, Mylan..
2017EXACT SCIENCES CORPORATION : Veröffentlichung des Halbjahresergebnisses
More news
Analyst Recommendations on EXACT SCIENCES CORPORATION
More recommendations
Chart EXACT SCIENCES CORPORATION
Duration : Period :
Exact Sciences Corporation Technical Analysis Chart | EXAS | US30063P1057 | MarketScreener
Technical analysis trends EXACT SCIENCES CORPORATION
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 16
Average target price 148,87 $
Last Close Price 145,97 $
Spread / Highest target 13,0%
Spread / Average Target 1,98%
Spread / Lowest Target -47,9%
EPS Revisions
Managers and Directors
NameTitle
Kevin T. Conroy Chairman, President & Chief Executive Officer
Ana Hooker Senior Vice President-Operations
Jeffrey Thomas Elliott Chief Financial Officer
Graham Peter Lidgard Chief Science Officer, SVP-Research & Development
Sandra Statz SVP-Clinical & Regulatory Affairs
Sector and Competitors
1st jan.Capitalization (M$)
EXACT SCIENCES CORPORATION10.17%23 214
GUARDANT HEALTH, INC.23.60%15 925
INVITAE CORPORATION25.78%9 293
ADAPTIVE BIOTECHNOLOGIES CORPORATION10.08%8 903
BGI GENOMICS CO., LTD.13.25%8 900
IOVANCE BIOTHERAPEUTICS, INC.10.04%7 490